Ipca Laboratories Limited

NSEI:IPCALAB Stock Report

Market Cap: ₹404.6b

Ipca Laboratories Future Growth

Future criteria checks 4/6

Ipca Laboratories is forecast to grow earnings and revenue by 30.1% and 11.8% per annum respectively. EPS is expected to grow by 30% per annum. Return on equity is forecast to be 15.1% in 3 years.

Key information

30.1%

Earnings growth rate

30.0%

EPS growth rate

Pharmaceuticals earnings growth17.6%
Revenue growth rate11.8%
Future return on equity15.1%
Analyst coverage

Good

Last updated04 Dec 2024

Recent future growth updates

Recent updates

Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price

Dec 20
Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17
Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Sep 20
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Aug 31
Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Jun 22
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

May 28
Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Mar 15
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20
These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26
How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13
Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28
Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23
Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11
Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30
Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Earnings and Revenue Growth Forecasts

NSEI:IPCALAB - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027113,71014,72310,36713,75117
3/31/2026101,32911,7159,10212,90419
3/31/202589,3958,9348,17312,20119
9/30/202485,3436,6128,97714,414N/A
6/30/202482,1335,768N/AN/AN/A
3/31/202477,0595,4745,3419,447N/A
12/31/202371,8755,643N/AN/AN/A
9/30/202366,8064,9222,6126,767N/A
6/30/202362,5004,911N/AN/AN/A
3/31/202362,4814,7133,1138,058N/A
12/31/202260,2255,250N/AN/AN/A
9/30/202259,0706,1422,3987,616N/A
6/30/202258,5057,205N/AN/AN/A
3/31/202258,3058,8413,7718,561N/A
12/31/202156,5619,152N/AN/AN/A
9/30/202156,3559,8373,7288,554N/A
6/30/202154,52110,005N/AN/AN/A
3/31/202154,20711,4007,28610,901N/A
12/31/202053,80210,647N/AN/AN/A
9/30/202051,8339,9687,37110,767N/A
6/30/202051,0619,228N/AN/AN/A
3/31/202046,4996,0632,6415,704N/A
12/31/201944,5636,189N/AN/AN/A
9/30/201942,4965,8042,8775,181N/A
6/30/201939,7775,059N/AN/AN/A
3/31/201937,7504,4483,2055,010N/A
3/31/201832,8522,394N/A3,411N/A
3/31/201731,5621,945N/A2,819N/A
3/31/201628,671931N/A7,087N/A
3/31/201531,4442,542N/A4,682N/A
3/31/201432,8184,785N/A5,223N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPCALAB's forecast earnings growth (30.1% per year) is above the savings rate (6.7%).

Earnings vs Market: IPCALAB's earnings (30.1% per year) are forecast to grow faster than the Indian market (18.1% per year).

High Growth Earnings: IPCALAB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: IPCALAB's revenue (11.8% per year) is forecast to grow faster than the Indian market (10.6% per year).

High Growth Revenue: IPCALAB's revenue (11.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IPCALAB's Return on Equity is forecast to be low in 3 years time (15.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 11:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ipca Laboratories Limited is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aditya KhemkaAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited
Sanjeev ChiniwarAnand Rathi Shares and Stock Brokers Limited